N-acetylcysteine as a potential treatment for novel coronavirus disease 2019Commentary Published on 2020-07-142022-10-31 Journal: Future Microbiology [Category] COVID-19, SARS, [키워드] COVID-19 N-acetylcysteine novel coronavirus disease Potential treatment SARS-CoV-2 [DOI] 10.2217/fmb-2020-0074 PMC 바로가기 [Article Type] Commentary
Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agentsResearch article Published on 2020-07-012022-10-05 Journal: Medical Hypotheses [Category] 치료제, [키워드] antibody antiviral agent Antiviral agents blocking Blood Cancer cancers CD8 CD8+ CD8+ cell Cell Chloroquine clinical trials COVID-19 COVID-19 infected patient COVID-19 patient CTLs cytokine secretion cytotoxic cytotoxicity disease Disease progression effective functional generate healthy controls healthy individuals Host immune response Immunity individual inhibiting inhibitory Innate innate immune response Innate immunity interferon lymphocyte mechanism mild infection modulated Monalizumab natural neutrophil NK cell NK cell function NK cells NKG2A Novel coronavirus outbreak over-expressing overexpression Patient Phase 2 Potential treatment receptor receptors reduced required resulting SARS SARS-CoV-2 severe COVID-19 Severe infection Side effect significantly significantly lower T-cell treated tumor growth tumor progression viral pathogen viruses weakened immune system [DOI] 10.1016/j.mehy.2020.109777 [Article Type] Research article
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?Case report Published on 2020-07-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] SARS, 치료법, [키워드] China Clinical prognosis complications coronavirus 2 COVID-19 COVID-19 affected patients D-dimer death discharged disease effective Elderly patient elevated high risk higher risk Hospitalization lymphopenia Mild Multiple multiple sclerosis no symptoms pandemic Patient patients with comorbidity potential therapy Potential treatment respiratory Result sclerosis Support Symptom tested the patient therapy thought treated Treatment type 1 interferon [DOI] 10.1016/j.msard.2020.102196 [Article Type] Case report
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?Case report Published on 2020-07-012022-10-05 Journal: Multiple sclerosis and related disorders [Category] SARS, 유전자 메커니즘, [키워드] B cell B-cell Clinical deterioration Complete Complication coronavirus disease 19 COVID-19 COVID-19 affected patients death depleting discharged disease disease entity Elderly patient Follow-up high risk higher risk Hospitalization Hypothesis immune response Immunosuppressant Immunosuppression immunosuppressive infected patient monoclonal antibody multiple sclerosis occurred overactive Patient patient symptom patients with comorbidity Potential treatment Protective Result Support Symptom tested therapy treated [DOI] 10.1016/j.msard.2020.102120 [Article Type] Case report
Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL ProteaseArticle Published on 2020-06-242022-10-31 Journal: Computation (Basel, Switzerland) [Category] COVID-19, [키워드] 2019 novel coronavirus 3CL ACE-2 candidate Community computational coronavirus COVID-19 disease Ergotamine include Infection inhibition inhibitor Interaction outbreak Potential treatment protease Research S-protein SARS-CoV-2 seeking severely infected patients spike Spike protein the SARS-CoV-2 the spike protein Treatment View virus [DOI] 10.3390/computation8020053 PMC 바로가기 [Article Type] Article
Genetic variability of human angiotensin‐converting enzyme 2 (hACE2) among various ethnic populationsOriginal Article Published on 2020-06-182022-10-30 Journal: Molecular Genetics & Genomic Medicine [Category] COVID-19, MERS, SARS, [키워드] absence ACE gene ACE2 Affect allele frequency angiotensin angiotensin‐converting enzyme 2 appear Asian Asians binding binding free energy calculated Caucasians cellular entry changes in Characteristics Chinese clinical impact COVID‐19 COVID‐19 death demonstrated eight enzyme ethnic variation European examined explain expression expression level Factor functional Gene Expression Generalizability genetic difference Genetic polymorphism genetics hACE2 hACE2 receptor human populations implication in vitro Infection infections influence magnitude minor allele frequency Missense mutation Molecular dynamics simulation Mortality mutant Mutation Numerous paucity of data performed polymorphism Population Potential treatment Protein receptor Result S protein SARS‐CoV‐2 SARS‐CoV‐2 severity susceptibility target Variability variant Variation virus [DOI] 10.1002/mgg3.1344 PMC 바로가기 [Article Type] Original Article
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019Case Report Published on 2020-06-172022-10-31 Journal: Immunotherapy [Category] COVID-19, MERS, SARS, [키워드] acute phase reactant acute respiratory syndrome Clinical improvement coronavirus disease Coronavirus disease 2019 COVID-19 cytokine-release syndrome develop disease effective GM-CSF granulocyte Hydroxychloroquine Hypoxemia hypoxic respiratory failure IL-6 increase in inflammatory markers lenzilumab Macrophage management monoclonal antibody Pneumonia Potential treatment Respiratory Support Result serum severe acute respiratory distress syndrome syndrome Tocilizumab treated Treatment with COVID-19 [DOI] 10.2217/imt-2020-0136 PMC 바로가기 [Article Type] Case Report
Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global CommunityReview Article Published on 2020-06-162022-10-29 Journal: Research [Category] COVID-19, [키워드] 2019 novel coronavirus 2019-nCoV amplification antibodies antigens cause caused clinical trial coronavirus Coronavirus disease 2019 COVID-19 CRISPR Critical detect detection diagnosis of COVID-19 difficulty breathing Disease diagnosis dry cough effective effort expand fatality Fever Health Intervention isothermal amplification Loss of Smell nucleic acids Other outbreak outcomes palindromic repeat pandemic polymerase Potential treatment progression reduce Respiratory illness RPA RT-PCR severe cases Spread Symptom Treatment Vaccine viral disease WHO World Health Organization [DOI] 10.34133/2020/6925296 PMC 바로가기 [Article Type] Review Article
Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid reviewResearch Published on 2020-06-082022-10-28 Journal: BJGP Open [Category] COVID-19, [키워드] Chloroquine clinical trial Clinicians conducted coronavirus COVID-19 determine disease effective Effectiveness Evidence General practice Google Google Scholar HCQ Hydroxychloroquine in vitro activity in vivo Long-term follow-up medical treatment medications medium methodological limitations novel pandemic participant patients Potential treatment Primary Healthcare randomised clinical trial required Result Safe SARS-CoV-2 secondary care treat treating COVID-19 Treatment treatments for COVID-19 Trial Vaccine WHO World Health Organization [DOI] 10.3399/bjgpopen20X101069 PMC 바로가기 [Article Type] Research
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronavirusesReview article Published on 2020-06-012022-10-05 Journal: One Health [Category] 치료제, [키워드] accumulate Antiviral antiviral drug Antiviral effect approved clinical trial clinical trials Community compassionate use coronavirus coronavirus disease Coronaviruses COVID-19 current demonstrated Epidemics Evidence GS-441524 GS-5734 illness imperative in vitro in vivo information International knowledge mitigate one health pandemic pandemic progresses Potential treatment Practitioner public health recent Regulatory Remdesivir SARS-CoV-2 tested therapeutic option Therapies Treatment Vaccine development [DOI] 10.1016/j.onehlt.2020.100128 [Article Type] Review article